Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (EMPIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02222948
Recruitment Status : Terminated (Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.)
First Posted : August 22, 2014
Last Update Posted : December 21, 2016
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : April 2016
Actual Study Completion Date : July 2016
Certification/Extension First Submitted : December 20, 2016